Patents Assigned to AFFIRIS AG
-
Publication number: 20220073650Abstract: Disclosed is an apheresis device including a solid carrier capable of being contacted with the blood or plasma flow, characterised in that the solid carrier includes one or several HTT-binding molecule (s) capable of adsorbing HTT or fragments thereof in a specific manner from plasma or blood or other HTT containing body fluids such as CSF.Type: ApplicationFiled: November 5, 2021Publication date: March 10, 2022Applicant: AFFIRIS AGInventors: Oskar SMRZKA, Stefan BARTL, Michela PARTH
-
Patent number: 11065273Abstract: The invention discloses an aluminium salt for use in the treatment and prevention of dementias associated with ?-amyloid deposition, preferably AD.Type: GrantFiled: April 29, 2015Date of Patent: July 20, 2021Assignee: AFFIRIS AGInventors: Markus Mandler, Achim Schneeberger, Wolfgang Zauner, Arne Von Bonin, Frank Mattner, Walter Schmidt
-
Publication number: 20210138048Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.Type: ApplicationFiled: January 11, 2021Publication date: May 13, 2021Applicant: AFFIRIS AGInventors: Sylvia BRUNNER, Gergana GALABOVA, Gabriele WINSAUER, Erika BILCIKOVA, Claudia JUNO, Pola LINZMAYER-HIRT, Birgit SCHUH, Guenther STAFFLER
-
Patent number: 10933123Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.Type: GrantFiled: May 21, 2018Date of Patent: March 2, 2021Assignee: AFFIRIS AGInventors: Sylvia Brunner, Gergana Galabova, Gabriele Winsauer, Erika Bilcikova, Claudia Juno, Pola Linzmayer-Hirt, Birgit Schuh, Guenther Staffler
-
Publication number: 20210040236Abstract: Disclosed is an apheresis device including a solid carrier capable of being contacted with the blood or plasma flow, characterised in that the solid carrier includes one or several HTT-binding molecule(s) capable of adsorbing HTT or fragments thereof in a specific manner from plasma or blood or other HTT containing body fluids such as CSF.Type: ApplicationFiled: August 18, 2020Publication date: February 11, 2021Applicant: AFFIRIS AGInventors: Oskar SMRZKA, Stefan Bartl, Michela Parth
-
Publication number: 20200338192Abstract: Disclosed is a method for the treatment of AD, wherein an immune stimulating pharmaceutical composition comprising an aluminium salt is administered to a patient having AD or having a risk to develop AD in an effective amount.Type: ApplicationFiled: March 17, 2020Publication date: October 29, 2020Applicant: AFFIRIS AGInventors: Markus MANDLER, Achim SCHNEEBERGER, Frank MATTNER, Walter SCHMIDT
-
Publication number: 20200254076Abstract: A method of treating a synucleinopathy with a peptide (C)DQPVLPD (SEQ ID NO: 59), (C)DMPVLPD (SEQ ID NO: 60), (C)DSPVLPD (SEQ ID NO: 61), (C)DQPVLPDN (SEQ ID NO: 64), (C)DMPVLPDN (SEQ ID NO: 65), (C)DSPVLPDN (SEQ ID NO: 66), (C)HDRPVTPD (SEQ ID NO: 70), (C)DRPVTPD (SEQ ID NO: 71), (C)DVPVLPD (SEQ ID NO: 72), (C)DTPVYPD (SEQ ID NO: 73), (C)DTPVIPD (SEQ ID NO: 74), (C)HDRPVTPDN (SEQ ID NO: 75), (C)DRPVTPDN (SEQ ID NO: 76), (C)DVPVLPDN (SEQ ID NO: 78), (C)DTPVYPDN (SEQ ID NO: 79), (C)DQPVLPDG (SEQ ID NO: 81), (C)DMPVLPDG (SEQ ID NO: 82), (C)DSPVLPDG (SEQ ID NO: 83), (C)DHPVHPDS (SEQ ID NO: 86), (C)DMPVSPDR (SEQ ID NO: 87), (C)DRPVYPDI (SEQ ID NO: 90), (C)DHPVTPDR (SEQ ID NO: 91), (C)DTPVLPDS (SEQ ID NO: 93), (C)DMPVTPDT (SEQ ID NO: 94), (C)DAPVTPDT (SEQ ID NO: 95), (C)DSPVVPDN (SEQ ID NO: 96), (C)DLPVTPDR (SEQ ID NO: 97), (C)DSPVHPDT (SEQ ID NO: 98), (C)DAPVRPDS (SEQ ID NO: 99), (C)DMPVWPDG (SEQ ID NO: 100), (C)DRPVQPDR (SEQ ID NO: 102), (C)YDRPVQPDR (SEQ ID NO: 103), (C)DMPVDADN (SEQ ID NO: 105), DQPVLPD(C) (SEType: ApplicationFiled: December 11, 2019Publication date: August 13, 2020Applicant: AFFIRIS AGInventors: Markus MANDLER, Harald WENINGER, Radmila SANTIC, Edith KOPINITS
-
Patent number: 10646565Abstract: Disclosed is a method for the treatment of AD, wherein an immune stimulating pharmaceutical composition comprising an aluminium salt is administered to a patient having AD or having a risk to develop AD in an effective amount.Type: GrantFiled: April 29, 2015Date of Patent: May 12, 2020Assignee: AFFIRIS AGInventors: Markus Mandler, Achim Schneeberger, Frank Mattner, Walter Schmidt
-
Patent number: 10576131Abstract: Disclosed is a vaccine, preferably for use in the prevention or treatment of an interleukin 23 (IL-23) related disease, that includes a peptide bound to a pharmaceutically acceptable carrier, wherein the peptide is QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322), GHHWETQQIPSLSPSQPWQRL QPEGHHWETQ (SEQ ID No. 98; p8461), TQQIPSLSPSQ (SEQ ID No. 99; p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100; p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101; p9269-C1), or QPEGHHWETQQIPSLSP (SEQ ID No. 102; p9269-C2), especially QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322) and wherein the IL-23 related disease is one or more of psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, preferably type 1 diabetes, atherosclerosis, inflammatory bowel disease (IBD)/M.Type: GrantFiled: June 3, 2016Date of Patent: March 3, 2020Assignee: AFFIRIS AGInventors: Guenther Staffler, Dorian Winter
-
Publication number: 20200016249Abstract: Disclosed is a vaccine, preferably for use in the prevention or treatment of an interleukin 23 (IL-23) related disease, comprising a peptide bound to a pharmaceutically acceptable carrier, wherein said peptide is selected from the group QPEGHH-WETQQIPSLS (SEQ ID No. 103; p8322), GHHWETQQIPSLSPSQPWQRL QPEGHHWETQ (SEQ ID No. 98; p8461), TQQIPSLSPSQ (SEQ ID No. 99; p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100; p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101; p9269-C1), and QPEGHHWETQQIPSLSP (SEQ ID No. 102; p9269-C2), especially QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322) and wherein said IL-23 related disease is selected from the group psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, preferably type 1 diabetes, atherosclerosis, inflammatory bowel disease (IBD)/M.Type: ApplicationFiled: July 8, 2019Publication date: January 16, 2020Applicant: AFFIRIS AGInventors: Guenther STAFFLER, Dorian WINTER
-
Patent number: 10517935Abstract: A method of treating a synucleinopathy with a peptide (C)DQPVLPD (SEQ ID NO: 59), (C)DMPVLPD (SEQ ID NO: 60), (C)DSPVLPD (SEQ ID NO: 61), (C)DQPVLPDN (SEQ ID NO: 64), (C)DMPVLPDN (SEQ ID NO: 65), (C)DSPVLPDN (SEQ ID NO: 66), (C)HDRPVTPD (SEQ ID NO: 70), (C)DRPVTPD (SEQ ID NO: 71), (C)DVPVLPD (SEQ ID NO: 72), (C)DTPVYPD (SEQ ID NO: 73), (C)DTPVIPD (SEQ ID NO: 74), (C)HDRPVTPDN (SEQ ID NO: 75), (C)DRPVTPDN (SEQ ID NO: 76), (C)DVPVLPDN (SEQ ID NO: 78), (C)DTPVYPDN (SEQ ID NO: 79), (C)DQPVLPDG (SEQ ID NO: 81), (C)DMPVLPDG (SEQ ID NO: 82), (C)DSPVLPDG (SEQ ID NO: 83), (C)DHPVHPDS (SEQ ID NO: 86), (C)DMPVSPDR (SEQ ID NO: 87), (C)DRPVYPDI (SEQ ID NO: 90), (C)DHPVTPDR (SEQ ID NO: 91), (C)DTPVLPDS (SEQ ID NO: 93), (C)DMPVTPDT (SEQ ID NO: 94), (C)DAPVTPDT (SEQ ID NO: 95), (C)DSPVVPDN (SEQ ID NO: 96), (C)DLPVTPDR (SEQ ID NO: 97), (C)DSPVHPDT (SEQ ID NO: 98), (C)DAPVRPDS (SEQ ID NO: 99), (C)DMPVLPDG (SEQ ID NO: 100), (C)DRPVQPDR (SEQ ID NO: 102), (C)YDRPVQPDR (SEQ ID NO: 103), (C)DMPVDADN (SEQ ID NO: 105), DQPVLPD(C) (SEType: GrantFiled: December 12, 2016Date of Patent: December 31, 2019Assignee: AFFIRIS AGInventors: Markus Mandler, Harald Weninger, Radmila Santic, Edith Kopinits
-
Patent number: 10478454Abstract: The invention discloses aluminium oxyhydroxide for use in the treatment and prevention of AD.Type: GrantFiled: April 29, 2015Date of Patent: November 19, 2019Assignee: AFFIRIS AGInventors: Markus Mandler, Achim Schneeberger, Arne Von Bonin, Frank Mattner, Walter Schmidt
-
Patent number: 10406197Abstract: Disclosed are immunogenic peptides of the HTT protein and HTT specific antibodies for use in the prevention and/or treatment of Huntington's disease.Type: GrantFiled: July 10, 2015Date of Patent: September 10, 2019Assignee: AFFIRIS AGInventors: Oskar Smrzka, Stefan Bartl, Michela Parth
-
Patent number: 10344062Abstract: The present invention relates to a vaccine comprising at least one peptide consisting of 7 to 19 amino acid residues consisting of the amino acid sequence (X3)mKDX2QLGX1 (SEQ ID No. 99), wherein X1 is an amino acid residue selected from the group consisting of alanine, asparagine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, serine, threonine, tyrosine and valine, X2 is an amino acid residue selected from the group consisting of alanine, arginine, histidine, isoleucine, leucine, lysine, methionine, threonine, tyrosine and valine. X3 is (X4)nANISX5 (SEQ ID No. 100) or an N-terminal truncated fragment thereof consisting of 1 to 4 amino acid residues, X4 is VVASQLR (SEQ ID No.Type: GrantFiled: May 23, 2013Date of Patent: July 9, 2019Assignee: AFFIRIS AGInventors: Guenther Staffler, Christine Landlinger, Frank Mattner
-
Publication number: 20190127438Abstract: Disclosed is an alpha chain of the human high-affinity IgE receptor (FceRIa), wherein the amino acid lysine at position 43 (K43) is exchanged with an amino acid selected from the group consisting of alanine, serine, tyrosine, isoleucine, leucine, asparagine, aspartic acid, methionine, phenylalanine, glutamic acid, threonine, glutamine, tryptophan, glycine, and valine, preferably alanine, glycine, serine or tyrosine, especially alanine.Type: ApplicationFiled: January 13, 2017Publication date: May 2, 2019Applicant: AFFIRIS AGInventors: Oskar SMRZKA, Marwa MOSTAGEER
-
Publication number: 20190091306Abstract: Disclosed is a method for vaccination against a self-antigen in a human patient wherein a dose with an effective amount of a self-antigen is administered to the patient to elicit a primary immune response, characterised in that the patient is subjected to a boost administration of said self-antigen, wherein the amount of the self-antigen in the dose for the boost administration is higher than the amount of the self-antigen in the dose used in the administration for the primary immune response.Type: ApplicationFiled: November 2, 2016Publication date: March 28, 2019Applicant: AFFIRIS AGInventors: Gergana GALABOVA, Sabine SCHMIDHUBER, Achim SCHNEEBERGER, Arne VON BONIN, Dorian WINTER, Jana ZIMMERMANN
-
Publication number: 20180327513Abstract: Disclosed is an apheresis device including a solid carrier capable of being contacted with the blood or plasma flow, characterised in that the solid carrier includes one or several HTT-binding molecule(s) capable of adsorbing HTT or fragments thereof in a specific manner from plasma or blood or other HTT containing body fluids such as CSF.Type: ApplicationFiled: July 2, 2018Publication date: November 15, 2018Applicant: AFFIRIS AGInventors: Oskar SMRZKA, Stefan Bartl, Michela Parth
-
Publication number: 20180289781Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.Type: ApplicationFiled: May 21, 2018Publication date: October 11, 2018Applicant: AFFIRIS AGInventors: Sylvia Brunner, Gergana Galabova, Gabriele Winsauer, Erika Bilcikova, Claudia Juno, Pola Linzmayer-Hirt, Birgit Schuh, Guenther Staffler
-
Patent number: 10053518Abstract: Disclosed is an apheresis device comprising a solid carrier capable of being contacted with the blood or plasma flow, characterised in that the solid carrier includes one or several HTT-binding molecule(s) capable of adsorbing HTT or fragments thereof in a specific manner from plasma or blood or other HTT containing body fluids such as CSF.Type: GrantFiled: July 10, 2015Date of Patent: August 21, 2018Assignee: AFFIRIS AGInventors: Oskar Smrzka, Stefan Bartl, Michela Parth
-
Publication number: 20180186896Abstract: Disclosed is a vaccine for use in the prevention or treatment of an Immunoglobulin E (IgE-) related disease, comprising a peptide bound to a pharmaceutically acceptable carrier, wherein said peptide is selected from the group of QQQGLPRAAGG (SEQ ID No. 109; p9347), QQLGLPRAAGG (SEQ ID No. 110; p8599), QQQGLPRAAEG (SEQ ID No. I11; p8600), QQLGLPRAAEG (SEQ ID No. 112; p8601), QQQGLPRAAG (SEQ ID No. 113; p9338), QQLGLPRAAG (SEQ ID No. 114; p9041), QQQGLPRAAE (SEQ ID No. 115; p9042), QQLGLPRAAE (SEQ ID No. 116; p9043), HSGQQQGLPRAAGG (SEQ ID No. 117; p7575), HSGQQLGLPRAAGG (SEQ ID No. 118; p8596), HSGQQQGLPRAAEG (SEQ ID No. 119; p8597), HSGQQLGLPRAAEG (SEQ ID No. 120; p8598), QSQRAPDRVLCHSG (SEQ ID No. 121; p7580), GSAQSQRAPDRVL (SEQ ID No. 122; p7577), and WPGPPELDV (SEQ ID No. 125; p7585).Type: ApplicationFiled: July 7, 2016Publication date: July 5, 2018Applicant: AFFIRIS AGInventors: Oskar SMRZKA, Benjamin VIGL